Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of smell - until a clinical trial worked wonders ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively increasing symptom burden, exercise limitations, and frequent ...

Dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13 pathways, has become a cornerstone treatment for AD. However, increasing reports of musculoskeletal complaints, including ...